Hereditary periodic fever syndromes in adult rheumatology practice
https://doi.org/10.14412/1996-7012-2018-1-78-84
Abstract
Autoinflammatory diseases (AIDs) are a heterogeneous group of rare genetically determined, hereditary conditions characterized by unprovoked inflammatory episodes that are manifested by recurrent fever and clinical symptoms reminiscent of rheumatic manifestations in the absence of autoimmune or infectious causes. The prevalence of hereditary AIDs in the population tends to increase. The list of AIDs is quite wide and includes various groups of diseases, including those faced by not only a pediatrician, but also by an adult rheumatology specialist. Practitioners do not know much about hereditary AIDs, so the latter are often diagnosed late. However, due to the clinical introduction of new diagnostic techniques, primarily genetic ones, and drug therapy in the detection and treatment of these diseases, there has been clear progress, which makes it possible to change long-term prognosis in AIDs and to arouse increasing interest in the diseases not only among pediatricians, geneticists, but also among rheumatologists and general practitioners.
About the Authors
O. V. Zhelyabina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
M. S. Eliseev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
M. N. Chikina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Fietta P. Autoinflammatory disease: thehereditary periodic fever syndromes. Acta Biomed. 2004 Aug;75(2):92-9.
2. Федоров ЕС, Салугина СО, Кузьмина НН. Аутовоспалительные синдромы: что необходимо знать ревматологу. Современная ревматология. 2012;6(2):49-59. [Fedorov ES, Salugina SO, Kuz'mina NN. Autoinflammatory syndromes: What a rheumatologist should know. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2012;6(2): 49-59. (In Russ.)]. doi: 10.14412/1996-7012-2012-728.
3. Simon A, van der Meer JW. Patogenesis of familial periodic fever syndromes or hereditary inflammatory syndromes. Am J Physiol Regul Integr Comp Physiol. 2007 Jan; 292(1):R86-98. Epub 2006 Aug 24.
4. Toplak N, Frenkel J, Ozen S, et al. An international registry on autoinflammatory diseases: the Eurofever experience. Ann Rheum Dis. 2012 Jul;71(7):1177-82. doi: 10.1136/annrheumdis-2011-200549. Epub 2012 Feb 29.
5. Gattorno M, Tassi S, Carta S, et al. Pattern of interleukin-1b secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum. 2007 Sep;56(9):3138-48. doi: 10.1002/art.22842
6. Насонов ЕЛ, Елисеев МС. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77. [Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2016;54(1):60-77. (In Russ.)]. doi: 10.14412/1995-4484-2016-60-77
7. Dinarello CA. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol. 2011 May;41(5):1203-17. doi: 10.1002/eji.201141550.
8. Mensa-Vilaro A, Teresa Bosque M, Magri G, et al. Late onset cryopyrin-associated periodic syndrome due to myeloidrestricted somatic NLRP3 mosaicism. Arthritis Rheumatol. 2016 Dec;68(12):3035- 3041. doi: 10.1002/art.39770.
9. Barron K, Athreya B, Kastner D. Periodic fever syndromes and other inherited autoinflammatory diseases. In: Cassidy JT, editor. Textbook of pediatric rheumatology. 6th ed. Elsevier Saunders; 2011. P. 642-60.
10. Kile RL, Rusk HA. A case of cold urticaria with unusual family history. JAMA. 1940;114:1067-8.
11. Yamauchi A, Iwata H, Ohnishi H, et al. Interleukin-17 expression in the urticarial rash of familial cold autoinflammatory syndrome: a case report. Br J Dermatol. 2010 Dec;163(6):1351-3. doi: 10.1111/j.1365-2133.2010.09978.x. Epub 2010 Nov 4.
12. Espandar L, Boehlke CS, Kelly MP. First report of keratitis in familial old autoinflammatory syndrome. Can J Ophthalmol. 2014 Jun;49(3):304-6. doi: 10.1016/j.jcjo.2014.01.007.
13. Gerbig AW, Dahinden CA, Mullis P, Hunziker T. Circadian elevation of IL-6 levels in Muckle-Wells syndrome: a disorder of the neuro-immune axis? QJM. 1998 Jul;91(7): 489-92.
14. Dode C, Le Du N, Cuisset L, et al. New mutations of CIAS that are responsible for Muckle- Wells syndrome and familial cold urticaria: a novel mutation underlies both syndrome. Am J Hum Genet. 2002 Jun;70(6): 1498-506. Epub 2002 Apr 25.
15. Салугина СО, Федоров ЕС, Кузьмина НН. Современные подходы к диагностике, лечению и мониторингу пациентов с криопирин-ассоциированными периодическими синдромами (CAPS). Современная ревматология. 2016;10(2):4-11. [Salugina SO, Fedorov ES, Kuz'mina NN. Current approaches to diagnosis, treatment, and monitoring in patients with cryopyrinassociated periodic syndromes (CAPS). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2016;10(2):4-11. (In Russ.)]. DOI:10.14412/1996-7012-2016-2-4-11.
16. Kuemmerle-Deschner JB, Koitschev A, Ummenhofer K, et al. Hearing loss in Muckle- Wells syndrome. Arthritis Rheum. 2013 Mar;65(3):824-31. doi:10.1002/art.37810.
17. Lieberman A, Grossman ME, Silvers DN. Muckle-Wells syndrome: case report and review of cutaneous pathology. J Am Acad Dermatol. 1998 Aug;39(2 Pt 1):290-1.
18. Goldbach-Mansky R, Daily NJ, Canna SW, et al. Neonatal-Onset Mutisystem Inflammatory Disease Responsive to Interleukine-1 Inhibition. N Engl J Med. 2006 Aug 10;355(6):581-92.
19. Goldbach-Mansky R, Shroff SD, Wilson M, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 2008 Aug;58(8): 2432-42. doi: 10.1002/art.23620.
20. Lachmann H, Kone-Paut I, Kuemmerle-Deschner GB, et al. for the Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009 Jun 4;360(23):2416-25. doi: 10.1056/NEJMoa0810787.
21. Simon A, Drewe E, van der Meer JW. Simvastatin Treatment for Inflammatory Attacks of the Hyperimmunoglobulinemia D and Periodic Fever Syndrome. Simvastatin Treatment for Inflammatory Attacks of the Hyperimmunoglobulinemia D and Periodic Fever Syndrome. Clin Pharmacol Ther. 2004 May;75(5):476-83.
22. Van der Meer JW, Vossen JM, Radl J, et al. Hyperimmunoglobulinemia D and periodic fever: a new syndrome. Lancet. 1984 May 19; 1(8386):1087-90.
23. Haas D, Hoffmans GF. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet J Rare Dis. 2006 Apr 26;1:13.
24. Arostegui JI, Anton J, Calvo I, et al. Open-Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome. Arthritis Rheumatol. 2017 Aug;69(8):1679-1688. doi: 10.1002/art.40146. Epub 2017 Jul 5.
25. Grateau G. Clinical and genetic aspects of the hereditary periodic fever syndromes. Rheumatology (Oxford). 2004 Apr;43(4):410-5. Epub 2004 Feb 24.
26. Kuijk LM, Hoffman HL, Neven B, Frenkel J. Episodic autoinflammatory disorders in children. In: Cimas R, Lehman T, editors. Handbook of Systemic Autoimmune Disease. Vol. 6 Pediatrcs in Systemic Autoimmune Disease. Elselvier; 2008. P. 119-35.
27. Kusuhara K, Nomura A, Nakao F, Hara T. Tumor necrosis factor receptor-associated periodic syndrome with a novel mutation in the TNFRSF1A gene in a Japanese family. Eur J Pediatr. 2004 Jan;163(1):30-2. Epub 2003 Nov 11.
28. Drenth G, van der Meer JW. Hereditary Periodic fever. N Engl J Med. 2001 Dec 13; І345(24):1748-57.
29. Gattorno M, Obici L, Cattalini M, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptorassociated periodic syndrome (TRAPS an op label, phase II study. Ann Rheum Dis. 2017 Jan; 76(1):173-178. doi: 10.1136/annrheumdis-2015-209031. Epub 2016 Jun 7.
30. La Torre F, Caparello MC, Cimaz R. Canakinumab for the treatment of TNF-receptor associated periodic syndrome. Expert Rev Clin Immunol. 2017 Jun;13(6):513-523. doi: 10.1080/1744666X.2017.1324783.
31. Drenth G, van der Meer JW. Hereditary Periodic fever. N Engl J Med. 2001 Dec 13; 345(24):1748-57.
32. Федоров ЕС, Салугина СО, Кузьмина НН. Семейная средиземноморская лихорадка (периодическая болезнь): современный взгляд на проблему. Современная ревматология. 2013;7(1):24-30. [Fedorov ES, Salugina SO, Kuz'mina NN. Familial Mediterranean fever (a periodic disease): The present-day view of the problem. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(1):24-30. (In Russ.)]. doi: 10.14412/1996-7012-2013-2363.
33. Арутюнян ВМ, Акопян ГС. Периодическая болезнь (этиопатогенетические и клинические аспекты). Москва: МИА; 2000. [Arutyunyan VM, Akopyan GS. Periodicheskaya bolezn' (etiopatogeneticheskie i klinicheskie aspekty) [Periodic disease (etiopathogenetic and clinical aspects)]. Moscow: MIA; 2000.]
34. Kalinich T, Haffer D, Niehues T, et al. Colchicine Use in Children and Adolescents With Familial Mediterranean Fever. Literature Review and Consensus Statement. Pediatrics. 2007 Feb;119(2):e474-83. Epub 2007 Jan 22.
35. Алекберова ЗС, Барскова ВГ. Колхицин в ревматологии – вчера и сегодня. Будет ли завтра? Современная ревматология. 2010;4(2):25-9. [Alekberova ZS, Barskova VG. Colchicine in rheumatology: yesterday and today. Will there be tomorrow? Sovremennaya revmatologiya = Modern Rheumatology Journal. 2010;4(2):25-9. (In Russ.)]. DOI:10.14412/1996-7012-2010-598.
36. Ozen S. Familial mediterranean fever: revisiting an ancient disease. Eur J Pediatr. 2002 Aug;161(8):449-54. Epub 2002 Jun 28.
37. Frenkel J, Kuijk L, Hofhuis W, et al. Anakinra in colchicin resistant Familial Mediterranean Fever in 14th European Paediatric Rheumatology Congress. Sept. 5-9, 2007. Istanbul. Abstr book:252.
38. Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR. Infliximab treatment of Familial Mediterranean Fever and its effect to secondary AA amyloidosis. J Clin Rheumatol. 2004 Jun;10(3):134-7.
39. Аствацатрян ВА, Торосян ЕХ. Периодическая болезнь у детей. Ереван: Айастан; 1989. [Astvatsatryan VA, Torosyan EKh. Periodicheskaya bolezn' u detei [Periodic disease in children]. Erevan: Aiastan; 1989.]
40. Akar S, Cetin P, Kalyoncu U. A Nationwide Experience With The Off-label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients. Arthritis Care Res (Hoboken). 2017 Oct 9. doi: 10.1002/acr.23446. [Epub ahead of print].
41. Ter Haar N, Lachmann H, Еzen S, et al. Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever/ Eurotraps ProjectsTreatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis. 2013 May;72(5):678-85. doi: 10.1136/annrheumdis-2011-201268. Epub 2012 Jun 29.
42. Ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015 Sep;74(9): 1636-44. doi: 10.1136/annrheumdis-2015-207546. Epub 2015 Jun 24.
43. De Benedetti F, Anton J, Gattorno M, et al. A Phase III, Pivotal, Umbrella Trial of Canakinumab in Patients With Auto-inflammatory Periodic Fever Syndromes (Colchicine- Resistant FMF, HIDS/MKD and TRAPS). Annals of the Rheumatic Diseases. 2016;75:615-6.
44. Lachmann H, Simon A, Anton J, et al. FRI0489 Canakinumab Improves Patient Reported Outcomes in Patients with Periodic Fever Syndromes. Annals of the Rheumatic Diseases. 2016;75:616.
45. Yildirim T, Yilmaz R, Uzerk Kibar M, Erdem Y. Canakinumab treatment in renal transplant recipients with familial Mediterranean fever. J Nephrol. 2018 Feb 14. doi: 10.1007/s40620- 018-0475-5. [Epub ahead of print].
Review
For citations:
Zhelyabina OV, Eliseev MS, Chikina MN. Hereditary periodic fever syndromes in adult rheumatology practice. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2018;12(1):78-84. (In Russ.) https://doi.org/10.14412/1996-7012-2018-1-78-84
Views:
1068
Email this article 